Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

Clinical Transplantation – Acute and Chronic GVHD, Infectious Complications, and Immune Reconstitution Poster II

Sunday, December 7, 2008: 6:00 PM-8:00 PM
Hall A (Moscone Center)
Hemorrhagic Cystitis and BK Virus Infection in Children after Hematopoietic Stem Cell Transplantation

Bernd Gruhn1*, Loreen Maier1*, Renate Egerer2*, Dietlinde Fuchs1*, Felix Zintl1* and James Beck1*

1Department of Pediatrics, University of Jena, Jena, Germany
2Institute for Virology and Antiviral Therapy, University of Jena, Jena, Germany

IFN-γ Induced by PHA Stimulation as New Marker for Gvhd Prediction in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Enrico Morello, MD1*, Vladia Monsurrò, Ph.D.2*, Elisabetta Pagani, Ph.D.3*, Irene Cavattoni, MD1*, Silvia Coin2*, Giuseppe Tridente, Prof.2*, Clara Larcher, MD3* and Sergio Cortelazzo, MD1*

1Div. of Hematology and BMT, Bolzano, Italy
2Institute of Immunology, University of Verona, Verona
3Laboratory of Microbiology and Virology, Bolzano

Reactivation of Cured Hepatitis B Virus after Allogeneic Hematopoietic Stem Cell Transplantation and Its Asociation with Liver Graft Versus Host Disease

Mariana Bastos Oreiro1*, Ana Lopez de la Guia1*, Miguel Canales III1, Raquel de Paz2*, Monica Martin Salces1*, Rosa Arrieta Gallastegui1* and Fernando Hernandez Navarro1*

1Hematology, Hospital Universitario La Paz, Madrid, Spain
2PETHEMA/Spanish Myeloma Group, Spain, Spain

Identification of New Minor Histocompatibility Antigens (mHags) in Patients with Chronic Graft Versus Host Disease (GvH) after Allogeneic Stem Cell Transplantation by SEREX

Joerg Thomas Bittenbring1*, Manfred Ahlgrimm1*, Markus Ditschkowski2*, Frank Neumann1*, Joerg Schubert1*, Klaus-Dieter Preuss1*, Dietrich Wilhelm Beelen, MD3* and Michael Pfreundschuh1

1Innere Medizin 1 Hämatologie/Onkologie, Unikliniken des Saarlandes, Homburg, Germany
2KMT Unit, University, Essen
3KMT Unit, University, Essen, Germany

Predominant Reconstitution of B Lymphoid Precursors (Hematogones) Following Unrelated Cord Blood Stem Cell Transplantation

Takahiro Shima, MD1*, Toshihiro Miyamoto, MD, PhD2, Yoshikane Kikushige, MD1*, Koji Nagafuji, MD, PhD1, Takanori Teshima, MD, PhD2 and Koichi Akashi, MD, PhD1*

1Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
2Center for Cellular and Molecular Medicine, Kyushu University Hospital, Fukuoka, Japan

Risk Factors and Survival Analyses of Ocular Graft-Versus-Host Disease (GVHD) in the Current Era of Allogeneic Stem Cell Transplant (SCT)

Madan Jagasia, MD, MS1, Sunny Mehrotra1*, Vinita Singh1*, Adetola A. Kassim, MD, MS2, Brian Engelhardt, MD, MS1, Sheri Dixon1* and Uyen Tran1*

1Vanderbilt Univ. Med. Ctr., Nashville, TN
2Vanderbilt University Medical Center, Nashville, TN

The Impact of NOD2/CARD15, TLR and IL23R   Polymorphisms on the Incidence of Infectious Complications in Allo-HSCT Recipients

Alexandra Maria Holowiecka-Goral1*, Sebastian Giebel1*, Jerzy Wojnar1*, Elzbieta Pietruszka1*, Agnieszka Karolczyk1*, Anna Soja1*, Tomasz Czerw1*, Jerzy Holowiecki2, Malgorzata Krawczyk-Kulis1*, Miroslaw Markiewicz1*, Wlodzimierz Mendrek1*, Beata Stella-Holowiecka1* and Slawomira Kyrcz-Krzemien1*

1Dept. of Haematology and BMT , Katowice Poland, Silesian Medical University, Katowice, Poland
2University Department of Hematology and BMT, Silesian Medical University, Katowice, Poland

Analysis of a New graft–versus‑host Disease (GvHD) Prophylaxis Regimen with Additional Enteric‑coated Mycophenolate Sodium (EC‑MPS) Starting 10 Days after Unrelated Allogeneic Stem Cell Transplantation

Herbert G. Sayer, Lars-Olof Mügge*, Sebastian Scholl*, Anne Klink*, Kristina Schilling* and Klaus Höffken*

Internal Medicine II (Oncology/Hematology), Universitätsklinikum Jena, Jena, Germany

Phase I Study of Transfer of CD8 Depleted Donor Leukocytes after Allogeneic Stem Cell Transplantation

Guillermo Orti, MD*, Karl Peggs, MD*, Kirsty Thomson, MD*, Emma Morris, MD*, Mark Lowdell, PhD*, Stephen Mackinnon, MD* and Ronjon Chakraverty, MD

Department of Haematology, University College London, London, United Kingdom

Reconstitution of Regulatory T Cells Involves in the Development of Acute Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplantation

Shuhei Karakawa, MD*, Kazuhiro Nakamura, MD*, Keiichi Hara, MD*, Yoko Mizoguchi, MD*, Mizuka Miki, MD*, Hiroshi Kawaguchi, MD*, Takashi Sato, MD*, Shin-ichiro Nishimura, MD* and Masao Kobayashi, MD, PhD

Pediatrics, Hiroshima University Graduate School of Biomedical Siensces, Hiroshima, Japan

Clinical Significance of Autoantibody Expression in Allogeneic Stem Cell Recipients

Joon Ho Moon1*, Soo Jung Lee1*, Jong Gwang Kim1*, Yee Soo Chae1*, Shi Nae Kim1*, Yun Jeong Kim1*, Young Rok Do2, Jang Soo Suh1*, Kun Soo Lee1* and Sang Kyun Sohn1*

1Hematology/Oncology, Kyungpook National University Hospital, Daegu, South Korea
2Hematology/Oncology, Dongsan Medical Center, Daegu, South Korea

The Promising Strategy of Mycophenolate Mofetil Dosing to Prevent Moderate- to Severe-Acute Graft-Versus-Host Disease

Shinichiro Nishikawa1*, Atsuo Okamura1*, Motohiro Yamamori2*, Yoshio Katayama1*, Manabu Shimoyama1* and Toshimitsu Matsui1

1Hematology/Oncology, Department of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
2Department of Hospital Pharmacy, Kobe University Hospital, Kobe, Japan

Multivirus-Specific T Cell Immunotherapy to Prevent or Treat Infections of Stem Cell Transplant Recipients

Ulrike Gerdemann, MD1*, Anne Christin, MD1*, Carlos A. Ramos, MD2, Yuriko Fujita, MD1*, Juan F. Vera, MD1*, Dagmar Dilloo, MD3, Malcolm K. Brenner, MD, PhD4*, Helen E. Heslop, MD4*, Cliona M. Rooney, PhD5* and Ann M. Leen, PhD1

1Pediatrics, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX
2Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX
3Heinrich-Heine University, Dusseldorf, Germany
4Pediatrics, Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX
5Pediatrics, Molecular Virology and Microbiology, Immunology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX

HHV6-Associated Limbic Encephalitis after Reduced-Intensity Umbilical Cord Blood TransplantationClinically Relevant Abstract

Kazuya Ishiwata, MD1*, Hisashi Yamamoto, MD1*, Shinsuke Takagi, MD1*, Masanori Tsuji, MD1*, Daisuke Kato, MD1*, Hideki Araoka, MD2*, Mayumi Yoshimi, MD1*, Madoka Narita1*, Kimiko Sagawa1*, Naofumi Matsuno, MD1*, Naoyuki Uchida, MD1, Kazuhiro Masuoka, MD1*, Atsushi Wake, MD1*, Akiko Yoneyama, MD2*, Shigeyoshi Makino, MD3* and Shuichi Taniguchi, MD, PhD1*

1Department of Hematology, Toranomon Hospital, Tokyo, Japan
2Department of Infectious Diseases, Toranomon Hospital, Tokyo, Japan
3Department of Transfusion Medicine, Toranomon Hospital, Tokyo, Japan

Association of Mannose Binding Lectin (MBL-2) Deficiency with Pulmonary Infection after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Dick Chung1*, Lily Ding2*, Isabelle Amigues1*, Katuna Kadeishvili1*, Theresa Lo1*, Eric Pamer1*, Stacey Kalambakas, MD2, Aby Buchbinder, MD2 and Genovefa Papanicolaou1*

1Service of Infectious Disease, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, NY
2Enzon Pharmaceuticals, Inc, Bridgewater, NJ

High Overall Response Rate in Calcineurin Inhibitor-Free Treatment with the mTOR Inhibitor Everolimus in Advanced Extensive Chronic GvHD after Allogeneic Stem Cell Transplantation

Anne Klink*, Kristina Schilling*, Katrin Rapp*, Klaus Höffken* and Herbert G. Sayer

Internal Medicine II (Oncology/Hematology), Universitätsklinikum Jena, Jena, Germany

Significantly Reduce Acute Graft-Versus-Host Disease in Haploidentical Stem Cell Transplantation by Using Cord Blood as the Third Party Cells

Dao-Pei Lu1*, Tong Wu1, Zhi-Yong Gao2*, Jing-Bo Wang1*, Xing-Yu Cao1*, Yan-Li Zhao1*, Lujia Dong2*, Yu-Ming Yin1*, Shu-Quan Ji1* and Wan-Ming Da1*

1Beijing Daopei Hospital, Beijing, China
2Shanghai Daopei Hospital, Shanghai, China

Evidence of a Significant Contribution of Thymic Output to T Cell Reconstitution Following Full Haplotype Mismatched Stem Cell Transplant (HSCT) Leading to a Predominantly Naïve Phenotype

Maria V.D. Soares1*, Rita I Azevedo1*, Rita Tendeiro1*, Rui S Soares1*, Rui MM Victorino1*, Joao F Lacerda2* and Ana E Sousa1*

1Unidade de Imunologia Clínica, Instituto de Medicina Molecular, Lisboa, Portugal
2Unidade Unidade de Imunologia Clínica and Serviço de Hematologia e Transplante de Medula Ossea, Instituto de Medicina Molecular and Hospital de Santa Maria, Lisboa, Lisboa, Portugal

Cytomegalovirus (CMV)-Specific CD8+ T Cells Are Associated with Control of Viral Reactivation Post-Hemopoietic Stem Cell Transplantation (HSCT) Only If Shown to Be Functionally Active

Stephanie Verfuerth, PhD1*, Karl S Peggs, MD2*, Arnold Pizzey2*, Noha Chowdhry1* and Stephen Mackinnon, MD1

1Royal Free & UCMS, London, United Kingdom
2University College London Cancer Institute, United Kingdom

Use of the Tetanus Toxoid, Reduced Dose Diphtheria and Pertussis Vaccine (Tdap) in Allogeneic Transplant (alloHCT) Recipients

Esperanza B Papadopoulos, MD1, James W Young, MD1*, Nancy A. Kernan, MD2, Farid Boulad, MD2*, H.R. Castro-Malaspina, MD1, Richard J O'Reilly, MD2*, Susan Prockop, MD2, Andromachi Scaradavou, MD2*, Joanne Taylor, RN, CNS1*, Ruth Ford, RN, CNS1*, Bernadette Cuello, NP-C1* and Trudy N Small, MD2*

1Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
2Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY

Clinical Outcome of Aspergillus-Specific Cytotoxic T Lymphocytes for Refractory Invasive Aspergillosis in Patients with Hematological Malignancies

Tong Wu1, Chun-Rong Tong1*, Xing-Yu Cao1*, Jing-Bo Wang1*, Lung-Ji Chang2*, Yin Liang3* and Dao-Pei Lu1*

1Beijing Daopei Hospital, Beijing, China
2Molecular Genetics and Microbiology, University of Florida, FL
3Vectorite Biomedica Inc., Taipei, Taiwan

Sirolimus-Containing Graft-Versus-Host Disease Prophylaxis and High-Resolution HLA Typing Improves the Outcome of Mismatched Unrelated Donor  Allogeneic Hematopoietic Stem Cell Transplantation

Ronald J. Maggiore, MD1, Dennis L. Cooper2*, Francine M. Foss2*, Warren D. Shlomchik2* and Stuart E. Seropian2*

1Hematology, Yale University School of Medicine, New Haven, CT
2Medical Oncology, Yale University School of Medicine, New Haven, CT

Assessment of Durability of Response in Patients with Skin Graft Versus Host Disease beyond Six Months Treatment with Extracorporeal Photopheresis: Reduction of Steroid Resistance and Evaluation of Long-Term Therapy on Survival

Youssef Sorour1* and Peter C Taylor2*

1Haematology Department, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
2Haematology Department, Rotherham General Hospital NHS Foundation Trust, Rotherham, United Kingdom

The Effect of Donor Lymphocyte Infusion Dose on the Occurrence of Severe Life-Threatening Acute Graft-Versus-Host Disease Early after Reduced Intensity Conditioning T Cell Depleted Stem Cell Transplantation

Peter A. Von Dem Borne, C.W.J. Ingrid Starrenburg*, M. Floor Beaumont*, Stijn J.M. Halkes, Erik W.A. Marijt*, J.H. Frederik Falkenburg* and Roelof Willemze

Department of Hematology, Leiden University Medical Center, Leiden, Netherlands

Association of Treatment with Sirolimus (SIR) and Calcineurin Inhibitor (CNI) for Prevention or Treatment of Graft-Vs-Host Disease (GVHD) with Transplant Associated Microangiopathy (TAM)

Joseph Rosenthal, Ellen Bolotin*, Anna Pawlowska*, Cheryl Oliver*, Sean Maroongroge* and Stephen Forman*

City of Hope, Duarte, CA

Early Lymphocyte Recovery Predicts Superior Survival after Unmanipulated HLA-Mismatched/Haploidentical Blood and Marrow Transplantation for Patients with Hematological Malignancies

Ying jun Chang*, Xiang yu Zhao*, Ming rui Huo*, Lan ping Xu*, Dai hong Liu*, Kai yan Liu* and Xiao Jun Huang, MD, PhD

Institute of Hematology, Beijing, China

Comparison of Immune Reconstitution after Unmanipulated HLA-Mismatched/ Haploidentical Blood and Marrow Transplantation and Unmanipulated HLA-Matched Sibling Transplantation in Patients with Hematological Malignancies

Ying jun Chang*, Xiang yu Zhao*, Ming rui Huo*, Xiao hua Luo*, Lan ping Xu*, Dai hong Liu*, Kai yan Liu* and Xiao Jun Huang, MD, PhD

Institute of Hematology, Beijing, China

Universal CD137 Expression upon Activation Allows Efficient Isolation of a Broad Repertoire of Virus-Specific CD8+ and CD4+ T Cells for Adoptive Immunotherapy

Maarten L. Zandvliet1*, J.H. Frederik Falkenburg2*, Inge Jedema2, Roelof Willemze2, Henk-Jan Guchelaar1* and Pauline Meij1*

1Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, Netherlands
2Department of Hematology, Leiden University Medical Center, Leiden, Netherlands

Improved Overall Survival in Patients Recovering with High Gamma/Delta T Cells after Allogeneic Haematopoietic Stem Cell Transplantation

Lambros Kordelas, MD1*, Matthias Junge2*, Rudolf Trenschel3*, Ahmet H Elmaagacli4 and Dietrich W Beelen5*

1University Hospital Essen, Department of Bone Marrow Transplantation, Essen, Germany
2Department of Bone Marrow Transplantation, University of Essen Medical School, Essen, Germany
3University Hospital of Essen, Department of Bone Marrow Transplantation, Germany
4BMT, University Hospital of Essen, Essen, Germany
5Department of Bone Marrow Transplantation, University Hospital Essen, Germany

Reactivation of Human Herpes Virus 6 (HHV6) during Hematopoietic Stem Cell Transplantation: Risk Factor Analysis of HHV6 Encephalitis and Survival

Yutaka Shimazu, MD1*, Takayuki Ishikawa, MD, PhD1*, Tatsuo Ichinohe, MD, PhD1, Tadakazu Kondo, MD, PhD2*, Kouhei Yamashita, MD, PhD2*, Wataru Maruyama, MD2* and Takashi Uchiyama, MD, PhD1

1Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
2Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Generation of Combined CD8+ and CD4+ T Cell Lines with High Specificity for Adenovirus Hexon Epitopes for Adoptive Immunotherapy after Allogeneic Stem Cell Transplantation

Maarten L. Zandvliet1*, J.H. Frederik Falkenburg2*, Louise A. Veltrop-Duits3*, Marco W. Schilham3*, Roelof Willemze2, Henk-Jan Guchelaar1* and Pauline Meij1*

1Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, Netherlands
2Department of Hematology, Leiden University Medical Center, Leiden, Netherlands
3Department of Pediatrics, Leiden University Medical Center, Leiden, Netherlands

Increase in Proportion of Th-17 Lymphocytes in Blood Heralds Overt Acute Graft Versus Host Disease in HSCT Patients

Andrzej Lange, MD, PhD1, Dorota Dlubek, PhD2*, Emilia Jaskula3*, Daria Drabczak-Skrzypek3*, Mariola Sedzimirska, MD, PhD4* and Janusz Lange, MD4*

1Clinical Immunology, Lower Silesian Center for Cellular Transplantation; Institute of Immunology and Experimental Therapy, Polish Academy of Science, Wroclaw, Poland
2Clinical Immunology, Institute of Immunology and Experimental Therapy, Polish Academy of Science; Lower Silesian Center for Cellular Transplantation, Wroclaw, Poland
3Clinical Immunology, Institute of Immunology and Experimental Therapy, Polish Academy of Science, Wroclaw, Poland
4Haematology, Transplantology, Lower Silesian Center for Cellular Transplantation, Wroclaw, Poland

Donor Type Impacts the Incidence of Severe Acute but Not Chronic Graft-Versus-Host Disease (GVHD) after Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplantation (ASCT) for Treatment of AML/MDS

Rima M. Saliba1*, Krishna V. Komanduri2*, Ebru Koca1*, Amin M. Alousi1*, Sergio Giralt1, Borje S. Andersson1*, Weiqing Zhang1*, Gabriela Rondon1*, Uday R. Popat1*, Partow Kebriaei1*, Marcos de Lima1* and Richard E. Champlin1*

1Stem Cell Transplantation and Cellular Therapy, UT MD Anderson Cancer Center, Houston, TX
2Adult Stem Cell Transplant Program, University of Miami Sylvester Cancer Center, Miami, FL

Plasmacytoid CD123+ Dendritic Cell Recovery Is An Independent Predictor of Survival after Unrelated Cord Blood Transplant (UCBT)

David A Wilfret, MD1*, Adam Mendizabal2*, Mel Reese1*, Richard Vinesett1*, Joanne Kurtzberg, MD3 and Paul Szabolcs, MD4

1PEDIATRIC BLOOD and MARROW TRANSPLANTATION, DUKE UNIVERSITY, Durham, NC
2The EMMES Corporation
3Duke University Medical Center, Durham, NC
4Duke Univ. Med. Ctr., Durham, NC

Cyclosporine a and Mycophenolate Mofetil Vs Cyclosporine a and Methotrexate as Gvhd Prophylaxis in Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation from HLA-Identical Sibling Donor

Jose Luis Piñana Sr.1*, David Valcarcel, MD2*, Rodrigo Martino3*, Francesc Fernandez4*, Pere Barba5*, Montserrat Rovira, MD, PhD6*, Enric Carreras, MD, PhD7*, Anna Sureda8* and Jorge Sierra, MD, PhD9*

1Hematology Clinical Division, Hospital de la santa creu i Sant Pau, Barcelona, Spain
2Hospital de la Santa Creu i Sant Pau (Edificio Nuevo), Barcelona, Italy
3Clinical Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
4Clinical Division of Hematology, hospital clinic de BArcelona, Barcelona, Spain
5Clinical Hematology, Hospital De Sant Pau, Barcelona, Spain
6GETH (Grupo Español de Trasplante Hematopoyético), PETHEMA (Programa Español de Tratamiento de Hemopatías Malignas), Barcelona, Spain
7GETH (Grupo Español de Transplante Hematopoyético), Hospital Clinic, Barcelona, Spain
8Hospital de Sant Pau, Hematology Department, Autonomous University of Barcelona, Barcelona, Spain
9Division of Clinical Hematology, Hospital de Santa Creu i Sant Pau, Barcelona, Spain

The Influence of Cytochrome P450 3A Gene Polymorphisms on Tacrolimus Concentrations in Hematopoetic Stem Cell Transplantation Patients

Masahiro Ogasawara*, Mizuha Kosugi*, Satomi Matsuoka*, Shinsuke Asamuma*, Shinsuke Noguchi*, Sirou Fujii*, Akinori Wada*, Shuichi Ota*, Masanobu Nakata*, Kiyotoshi Imai*, Naoki Kobayashi*, Yoshio Kiyama* and Masaharu Kasai*

Internal Medicine, Spporo Hokuyu Hospital, Sapporo, Japan

Increased Type I Interferon Signaling and Inflammatory Factors Associated with T-Bet+ Cytotoxic Effectors in Chronic Graft Versus Host Disease of Oral Mucosa

Matin M. Imanguli, DDS1*, William D. Swaim, PhD2*, Stacy League1*, Ronald E. Gress, MD1*, Steven Z. Pavletic, MD1 and Frances T. Hakim, PhD1*

1Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD
2Molecular Physiology and Therapeutics Branch, NIDCR, NIH, Bethesda, MD

Rituximab Prophylaxis of EBV Reactivation after Alternative Donor Transplants Following Anti-Thymocyte Globulin-Based Conditioning Regimens

Andrea Bacigalupo, MD, Alida Dominietto*, Monica Soracco*, Anna Maria Raiola*, Maria Teresa Van Lint*, Teresa Lamparelli*, Adalberto Ibatici*, Francesca Gualandi*, Francesco Frassoni* and Elisabetta Tedone*

Hem-Onc, Ospedale S. Martino, Genova, Italy

Early Prediction of Acute Gvhd Based on Molecular Profiling at the Time of Engraftment after Hematopoietic Stem Cell Transplantation

Adriano Moraes Arantes, MD1*, Gerdine Sanson, PhD2*, Amador Gonçalves Primo2*, José Salvador Rodrigues Oliveira, MD, PhD1*, Maria Gerbase DeLima, MD, PhD2*, Natalia Shulzhenko, MD, PhD3* and Andrey Morgun, MD, PhD3*

1Hematology Division, Federal University of Sao Paulo, Sao Paulo, Brazil
2Pediatrics Department, Immunogenetics Division, Federal University of Sao Paulo, Sao Paulo, Brazil
3"Ghost lab", LCMI, NIAID, NIH, Bethesda, MD

Rituximab Infusion Two Months after HCT Decreases Alloreactive B Cell Responses While Recipient Plasma Cells Persist

Bita Sahaf, PhD1*, Julie R. Boiko1*, George Chen, MD1*, Kartoosh Heydari, MD2*, Sally Arai, MD3 and David Miklos, MD, PhD1

1Stanford University School of Medicine, Stanford, CA
2Department of Pedicatrics, Division of Stem Cell Transplantation, Stanford, CA
3Bone Marrow Transplant, Stanford University Medical Center, Stanford, CA

A Randomized, Controlled Trial of Graft-Versus-Host Disease (GVHD) Prophylaxis Comparing Tacrolimus and Mycophenolate Mofetil to Tacrolimus and Methotrexate: Analysis of GVHD, Relapse and Survival

Janelle Perkins1*, Melissa Alsina1*, Claudio Anasetti1*, Ernesto Ayala1*, Hugo F. Fernandez1*, Mohamed Kharfan-Dabaja1*, Jose Leonel Ochoa-Bayona1*, Lia Perez1*, Jyotishankar Raychaudhuri1*, Dan Sullivan1*, Jongphil Kim2*, Michael Schell2* and Teresa Field1

1Blood and Marrow Transplantation, H.Lee Moffitt Cancer Center, Tampa, FL
2Biostatistics Core, H. Lee Moffitt Cancer Center, Tampa, FL

The Distribution of KIR Gene in Chinese Population and the Effect of Donor KIR and Patient HLA Genotypes on Outcome Following Allogeneic Hematopoietic Stem Cell Transplantation

He Huang, MD, PhD1, Gongqiang Wu1*, Xiaoyu Lai1*, Yamin Tan1*, Yi Luo1* and Faming Zhu2*

1Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, China

The FcγRllla Polymorphism Correlates with Chronic Graft-Versus-Host Disease and Treatment Related Mortality

Akiyoshi Takami, MD, PhD, J. Luis Espinoza, MD*, Ken Ishiyama, MD, PhD*, Satomi Ohyachi*, Yuki Kato*, Yoshimi Kawamura*, Yukio Kondo, MD, PhD*, Shizuka Yasue*, Shigeki Ohtake, MD, PhD* and Shinji Nakao, MD, PhD*

Cellular Transplantation Bio., Kanazawa Univ., Kanazawa, Japan

Functional Control of CMV Reactivation Is Profoundly Influenced by CMV Serostatus after Nonmyeloablative Hematopoietic Cell Transplantation Following a TLI-ATG Preparative Regimen

Joanna Schaenman, M.D., Ph.D.1*, Marcy L. Vana, Ph.D.2*, Chanu Rhee, M.D.3*, Jonathan Wong4*, Shelly Navato5*, Laura J. Johnston, M.D.5*, Ruby M. Wong5*, Dora Y. Ho, M.D., Ph.D.4* and Janice (Wes) Brown, M.D.1*

1Divisions of Infectious Diseases and Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, CA
2Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, CA
3Department of Medicine, Stanford University Medical Center
4Division of Infectious Diseases, Stanford University Medical Center, Stanford, CA
5Division of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, CA

Re-Evaluation of Chronic Graft-Versus-Host Disease Using National Institute of Health Consensus Criteria

Dae-Young Kim*, Je-Hwan Lee, Jung-Hee Lee*, Se Hyung Kim*, Sung-nam Lim*, Young-Shin Lee*, Young-Ah Kang*, Sol-Ip Kang*, Miee Seol*, Seong-Gil Ryu* and Kyoo-Hyung Lee*

Department of Hematology, Asan Medical Center University of Ulsan College of Medicine, Seoul, South Korea

Comparison of Cyclosporine and Methotrexate with Cyclosporine and Mycophenolate Mofetil for Gvhd Prophylaxis in Myeloablative Allogeneic Bone Marrow Transplantation

Robert Dean, Lisa Rybicki*, Ronald Sobecks, Edward Copelan, Matt Kalaycio, Steven Andresen*, Shawnda Sungren*, Mary Serafin* and Brian J. Bolwell

Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

*signifies non-member of ASH